COMPASS Pathways(CMPS) Stock Price Today

US Stock MarketDetailed Quotes

CMPS COMPASS Pathways

Watchlist

3.820
-0.170-4.26%

Close Apr 25 16:00 ET

354.01MMarket Cap-1.66P/E (TTM)

Pre-Market

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Why Compass Pathways Stock Was a Double-Digit Winner This Week
Yahoo FinanceApr 25 18:13 ET
Express News | Reported Earlier: 'Texas Lawmakers Take Up Bills To Expedite Access To Psychedelic Therapy' - Marijuana Moment
BenzingaApr 22 11:11 ET
Compass Pathways Completes Dosing in Part A of Phase 3 Psilocybin Trial
TipRanksApr 22 06:10 ET
Express News | Compass Pathways PLC - Top-Line 6-Week Primary Endpoint Results Expected in Late June
ReutersApr 22 06:02 ET
Express News | Compass Pathways Announces Dosing Complete for All Participants in Part a of Phase 3 Comp005 Trial of Comp360 Psilocybin for Treatment-Resistant Depression
ReutersApr 22 06:00 ET
Stifel Maintains COMPASS Pathways(CMPS.US) With Buy Rating, Maintains Target Price $11
Moomoo NewsApr 11 13:31 ET · Ratings

Comments

Teddy123

Apr 22 18:04

Compass Pathways Announces Dosing Complete for All Participants in Part A of Phase 3 COMP005 Trial of COMP360 Psilocybin for Treatment-Resistant Depression

$COMPASS Pathways (CMPS.US)$
Major Depression Breakthrough? Phase 3 Psilocybin Trial Completes Dosing, June Results Awaited

Trytosaveabit

Apr 22 18:01

update

$COMPASS Pathways (CMPS.US)$ Reuters· just
Compass Pathways Announces Dosing Complete for All Participants in Part a of Phase 3 Comp005 Trial of Comp360 Psilocybin for Treatment-Resistant Depression!
Compass Pathways PLC - Top-Line 6-Week Primary Endpoint Results Expected in Late June

Teddy123

Mar 26 18:34

Compass Pathways Announces Completion of Recruitment for the Phase 3 COMP005 Trial of COMP360 Psilocybin for Treatment-Resistant Depression

$COMPASS Pathways (CMPS.US)$
Breakthrough Depression Treatment Reaches Critical Phase 3 Milestone: COMP360 Psilocybin Trial Fully Enrolled

Jaguar8

Mar 26 18:30

NEWS

$COMPASS Pathways (CMPS.US)$
Compass Pathways Announces Completion of Recruitment for the Phase 3 COMP005 Trial of COMP360 Psilocybin for Treatment-Resistant Depression
Wednesday, 26th March at 6:30 am
Highlights:
• Screening closed for all sites and final participants being scheduled for dosing
• On track for top-line 6-week primary endpoint results in late Q2
Compass Pathways plc (NASDAQ: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation,...